

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9905822/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Outcomes in newly diagnosed young or high-risk myeloma patients receiving tandem autologous/allogeneic transplant followed by bortezomib maintenance: a phase II study. Bone Marrow Transplantation, 2022, 57, 252-260.	2.4	6
2	Early free light chain reduction following treatment initiation predicts favorable outcome in intact immunoglobulin myeloma. Blood Cancer Journal, 2022, 12, 3.	6.2	5
3	Real-World Outcomes of Autologous and Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma in the Era of Novel Therapies: A Canadian Perspective. Transplantation and Cellular Therapy, 2022, 28, 145-151.	1.2	4
4	UM171-Expanded Cord Blood Transplants Support Robust T Cell Reconstitution with Low Rates of Severe Infections. Transplantation and Cellular Therapy, 2021, 27, 76.e1-76.e9.	1.2	11
5	Evaluation of the Impact of Autologous Hematopoietic Stem Cell Transplantation on the Quality of Life of Older Patients with Lymphoma. Biology of Blood and Marrow Transplantation, 2020, 26, 157-161.	2.0	13
6	Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1–2 safety and feasibility study. Lancet Haematology,the, 2020, 7, e134-e145.	4.6	138
7	Single UM171â€expanded cord blood transplant can cure severe idiopathic aplastic anemia in absence of suitable donors. European Journal of Haematology, 2020, 105, 808-811.	2.2	3
8	Newly diagnosed multiple myeloma patients treated with tandem autoâ€allogeneic stem cell transplant have better overall survival with similar outcomes at time of relapse compared to patients who received autologous transplant only. Clinical Transplantation, 2020, 34, e14099.	1.6	4
9	UM171-Expanded Cord Blood Transplants Support Robust T-Cell Reconstitution with Low Rates of Severe Infections. Blood, 2020, 136, 36-37.	1.4	2
10	Allodepleted Tâ€cell immunotherapy after haploidentical haematopoietic stem cell transplantation without severe acute graftâ€versusâ€host disease (<scp>GVHD</scp>) in the absence of <scp>GVHD</scp> prophylaxis. British Journal of Haematology, 2019, 186, 754-766.	2.5	20
11	Outcome of autologous hematopoietic stem cell transplant in older patients with B cell lymphoma when selected for fitness and chemosensitive disease. Leukemia Research, 2019, 79, 75-80.	0.8	8
12	Double-Negative T Cell Levels Correlate with Chronic Graft-versus-Host Disease Severity. Biology of Blood and Marrow Transplantation, 2019, 25, 19-25.	2.0	16
13	High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia. Blood Cancer Journal, 2018, 8, 68.	6.2	36
14	New onset colitis in an adult patient with chronic granulomatous disease treated with hematopoietic stem cell transplantation: a diagnostic dilemma. Allergy, Asthma and Clinical Immunology, 2018, 14, 17.	2.0	0
15	Successful Treatment of Disseminated Anncaliia algerae Microsporidial Infection With Combination Fumagillin and Albendazole. Open Forum Infectious Diseases, 2016, 3, ofw158.	0.9	14
16	Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study. Lancet, The, 2014, 383, 436-448.	13.7	322
17	Safety and Cost-Effectiveness of Outpatient AutologousÂStem Cell Transplantation in Patients with Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2013, 19, 547-551.	2.0	60
18	Tandem Autologous–Allogeneic Nonmyeloablative Sibling Transplantation in Relapsed Follicular Lymphoma Leads to Impressive Progression-Free Survival with Minimal Toxicity. Biology of Blood and Marrow Transplantation, 2012, 18, 951-957.	2.0	23

N /	Δ	N
	 А	IN

#	Article	IF	CITATIONS
19	Incidence and Prognostic Value of Eosinophilia in Chronic Graft-versus-Host Disease after Nonmyeloablative Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2011, 17, 1673-1678.	2.0	27
20	Infusion of Mesenchymal Stromal Cells can Aid Hematopoietic Recovery Following Allogeneic Hematopoietic Stem Cell Myeloablative Transplant: A Pilot Study. Stem Cells and Development, 2009, 18, 1247-1252.	2.1	81
21	Preemptive Management of Epstein-Barr Virus Reactivation After Hematopoietic Stem-Cell Transplantation. Transplantation, 2009, 87, 1240-1245.	1.0	55